{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:19:26Z","timestamp":1783041566186,"version":"3.54.6"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Roche Italia \u201cFondazione Roche per la Ricerca Indipendente\u201d grant"},{"name":"Gruppo di Oncologia Geriatrico Italiano"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K22 CA237746"],"award-info":[{"award-number":["K22 CA237746"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K22 CA237746"],"award-info":[{"award-number":["K22 CA237746"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016958","name":"Office of Research Infrastructure Programs","doi-asserted-by":"publisher","award":["S10OD028685"],"award-info":[{"award-number":["S10OD028685"]}],"id":[{"id":"10.13039\/100016958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017453","name":"Institute for Prostate Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wong Family Award in Translational Oncology"},{"name":"Claudia Adams Barr Program in Cancer Research Innovative Basic Science Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    There are currently no clinically validated markers for taxane sensitivity in metastatic castration-resistant prostate cancer (mCRPC), so we aimed to predict docetaxel response from circulating cell-free DNA. We identified 180 patients with pre-treatment plasma specimens collected within 12 months of starting docetaxel for mCRPC at our institution. 138 underwent ultra-low pass whole genome sequencing (ULP-WGS), and tumor fractions (TFx) and copy number alterations (CNAs) were derived using ichorCNA. 79 samples with TFx &gt; 0.04 underwent targeted panel sequencing (TPS).\n                    <jats:italic>TP53<\/jats:italic>\n                    mutation was significantly associated with docetaxel non-response (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.018); deletions involving bands located in arms 11p, 11q, 10q and 3p were enriched in responders, and amplifications in regions of 1p and 6q were enriched in non-responders. Transcription factor (TF) binding activity was inferred using Griffin, which identified TFs (ZSCAN4, CTCF, PHOX2B) with trends towards increased activity in non-responders (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200922) and others (including PBX1, MYBL2, OSR2, PDX1 and ZIC2) in responders (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200924). A combined ensemble binary classifier generated through XGBoost integrating these feature sets to predict docetaxel response outperformed models derived from any single feature set, achieving a training area-under-the-ROC curve of 0.87. Pre-cabazitaxel specimens, representing a docetaxel-resistant population, were used for external validation, with a concordance of 79.6% for predicting non-response.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01454-6","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:12Z","timestamp":1777374492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"David D.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Francini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jett","family":"Crowdis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irbaz","family":"Bin Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hanratty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Rickles-Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Cibulskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fleharty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Whelpley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin W.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish D.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"1454_CR1","doi-asserted-by":"publisher","unstructured":"McManus, H. D. et al. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-024-00906-z (2024).","DOI":"10.1038\/s41391-024-00906-z"},{"key":"1454_CR2","doi-asserted-by":"publisher","unstructured":"Francini, E. et al. Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.008 (2024).","DOI":"10.1016\/j.eururo.2024.09.008"},{"key":"1454_CR3","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1007\/s12325-022-02073-w","volume":"39","author":"A Leith","year":"2022","unstructured":"Leith, A. et al. Real-world treatment patterns in metastatic castration-resistant prostate cancer across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan. Adv. Ther. 39, 2236\u20132255 (2022).","journal-title":"Adv. Ther."},{"key":"1454_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","volume":"27","author":"SJ Freedland","year":"2024","unstructured":"Freedland, S. J., Davis, M., Epstein, A. J., Arondekar, B. & Ivanova, J. I. Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 27, 327\u2013333 (2024).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1454_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1615\/CritRevOncog.2022043298","volume":"27","author":"A Davies","year":"2022","unstructured":"Davies, A., Azad, A. A. & Kwan, E. M. Genomic alterations to guide treatment selection in metastatic prostate cancer. Crit. Rev. Oncog. 27, 61\u201380 (2022).","journal-title":"Crit. Rev. Oncog."},{"key":"1454_CR6","doi-asserted-by":"publisher","unstructured":"Gillette, C. M., Yette, G. A., Cramer, S. D. & Graham, L. S. Management of advanced prostate cancer in the precision oncology era. Cancers 15, https:\/\/doi.org\/10.3390\/cancers15092552 (2023).","DOI":"10.3390\/cancers15092552"},{"key":"1454_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1053\/j.seminoncol.2023.09.003","volume":"51","author":"O Longoria","year":"2024","unstructured":"Longoria, O., Beije, N. & de Bono, J. S. PARP inhibitors for prostate cancer. Semin. Oncol. 51, 25\u201335 (2024).","journal-title":"Semin. Oncol."},{"key":"1454_CR8","doi-asserted-by":"publisher","unstructured":"Zacchi, F. et al. Recent and future developments in the use of poly (ADP-ribose) polymerase inhibitors for prostate cancer. Eur. Urol. Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.11.011 (2024).","DOI":"10.1016\/j.euo.2024.11.011"},{"key":"1454_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1\u201310 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1454_CR10","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus, L. et al. FDA Approval Summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin. Cancer Res. 27, 4685\u20134689 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1454_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41391-021-00430-4","volume":"25","author":"MG Velez","year":"2022","unstructured":"Velez, M. G. et al. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 25, 479\u2013483 (2022).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1454_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euo.2018.02.006","volume":"1","author":"P Rescigno","year":"2018","unstructured":"Rescigno, P. et al. Docetaxel treatment in PTEN- and ERG-aberrant metastatic prostate cancers. Eur. Urol. Oncol. 1, 71\u201377 (2018).","journal-title":"Eur. Urol. Oncol."},{"key":"1454_CR13","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.annonc.2021.06.003","volume":"32","author":"AA Hamid","year":"2021","unstructured":"Hamid, A. A. et al. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann. Oncol. 32, 1157\u20131166 (2021).","journal-title":"Ann. Oncol."},{"key":"1454_CR14","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1016\/j.cell.2025.07.042","volume":"188","author":"E Grist","year":"2025","unstructured":"Grist, E. et al. Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers. Cell 188, 5717\u20135734.e10 (2025).","journal-title":"Cell"},{"key":"1454_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213\u2013223 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1454_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","volume":"406","author":"N Agarwal","year":"2025","unstructured":"Agarwal, N. et al. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet 406, 447\u2013460 (2025).","journal-title":"Lancet"},{"key":"1454_CR17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1470-2045(25)00209-8","volume":"26","author":"N Agarwal","year":"2025","unstructured":"Agarwal, N. et al. Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. Lancet Oncol. 26, 860\u2013876 (2025).","journal-title":"Lancet Oncol."},{"key":"1454_CR18","doi-asserted-by":"publisher","unstructured":"Tombal, B. et al. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.011 (2025).","DOI":"10.1016\/j.annonc.2025.05.011"},{"key":"1454_CR19","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris, M. J. et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404, 1227\u20131239 (2024).","journal-title":"Lancet"},{"key":"1454_CR20","doi-asserted-by":"publisher","unstructured":"Angeles, A. K. et al. Liquid biopsies beyond mutation calling: genomic and epigenomic features of cell-free DNA in cancer. Cancers 13, https:\/\/doi.org\/10.3390\/cancers13225615 (2021).","DOI":"10.3390\/cancers13225615"},{"key":"1454_CR21","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/1538-7445.AM2024-972","volume":"84","author":"G Vlachos","year":"2024","unstructured":"Vlachos, G. et al. Non-invasive detection of homologous recombination deficiency in metastatic prostate cancer patients. Cancer Res. 84, 972\u2013972 (2024).","journal-title":"Cancer Res."},{"key":"1454_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00366-z","volume":"7","author":"EJ Ritch","year":"2023","unstructured":"Ritch, E. J. et al. A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. npj Precis. Oncol. 7, 27 (2023).","journal-title":"npj Precis. Oncol."},{"key":"1454_CR23","doi-asserted-by":"publisher","unstructured":"Liu, R. et al. DirectHRD enables sensitive scar-based classification of homologous recombination deficiency. Nucleic Acids Res. 53, https:\/\/doi.org\/10.1093\/nar\/gkaf313 (2025).","DOI":"10.1093\/nar\/gkaf313"},{"key":"1454_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8, 1324 (2017).","journal-title":"Nat. Commun."},{"key":"1454_CR25","doi-asserted-by":"publisher","unstructured":"Choudhury, A. D. et al. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight 3, https:\/\/doi.org\/10.1172\/jci.insight.122109 (2018).","DOI":"10.1172\/jci.insight.122109"},{"key":"1454_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2017.76.0033","volume":"36","author":"DG Stover","year":"2018","unstructured":"Stover, D. G. et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J. Clin. Oncol. 36, 543\u2013553 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1454_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41416-021-01635-z","volume":"126","author":"Y Liu","year":"2022","unstructured":"Liu, Y. At the dawn: cell-free DNA fragmentomics and gene regulation. Br. J. Cancer 126, 379\u2013390 (2022).","journal-title":"Br. J. Cancer"},{"key":"1454_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102085","volume":"49","author":"AS Sirajee","year":"2024","unstructured":"Sirajee, A. S., Kabiraj, D. & De, S. Cell-free nucleic acid fragmentomics: a non-invasive window into cellular epigenomes. Transl. Oncol. 49, 102085 (2024).","journal-title":"Transl. Oncol."},{"key":"1454_CR29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.annonc.2023.06.001","volume":"34","author":"KT Helzer","year":"2023","unstructured":"Helzer, K. T. et al. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. Ann. Oncol. 34, 813\u2013825 (2023).","journal-title":"Ann. Oncol."},{"key":"1454_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385\u2013389 (2019).","journal-title":"Nature"},{"key":"1454_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","volume":"40","author":"MS Esfahani","year":"2022","unstructured":"Esfahani, M. S. et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat. Biotechnol. 40, 585\u2013597 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1454_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","volume":"164","author":"MW Snyder","year":"2016","unstructured":"Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164, 57\u201368 (2016).","journal-title":"Cell"},{"key":"1454_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35076-w","volume":"13","author":"AL Doebley","year":"2022","unstructured":"Doebley, A. L. et al. A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA. Nat. Commun. 13, 7475 (2022).","journal-title":"Nat. Commun."},{"key":"1454_CR34","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2159-8290.CD-22-0692","volume":"13","author":"N De Sarkar","year":"2023","unstructured":"De Sarkar, N. et al. Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes. Cancer Discov. 13, 632\u2013653 (2023).","journal-title":"Cancer Discov."},{"key":"1454_CR35","doi-asserted-by":"publisher","unstructured":"Francini, E. et al. Circulating cell-free DNA as biomarker of taxane resistance in metastatic castration-resistant prostate cancer. Cancers 13, https:\/\/doi.org\/10.3390\/cancers13164055 (2021).","DOI":"10.3390\/cancers13164055"},{"key":"1454_CR36","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2326-6066.CIR-22-0306","volume":"12","author":"AD Choudhury","year":"2024","unstructured":"Choudhury, A. D. et al. Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer. Cancer Immunol. Res. 12, 704\u2013718 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"1454_CR37","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"J Armenia","year":"2018","unstructured":"Armenia, J. et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50, 645\u2013651 (2018).","journal-title":"Nat. Genet."},{"key":"1454_CR38","first-page":"676","volume":"3","author":"Y Sekino","year":"2020","unstructured":"Sekino, Y. & Teishima, J. Molecular mechanisms of docetaxel resistance in prostate cancer. Cancer Drug Resist. 3, 676\u2013685 (2020).","journal-title":"Cancer Drug Resist."},{"key":"1454_CR39","doi-asserted-by":"publisher","unstructured":"Lima, T. S. et al. Molecular profiling of docetaxel-resistant prostate cancer cells identifies multiple mechanisms of therapeutic resistance. Cancers 13, https:\/\/doi.org\/10.3390\/cancers13061290 (2021).","DOI":"10.3390\/cancers13061290"},{"key":"1454_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ccr.2012.07.016","volume":"22","author":"J Domingo-Domenech","year":"2012","unstructured":"Domingo-Domenech, J. et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 22, 373\u2013388 (2012).","journal-title":"Cancer Cell"},{"key":"1454_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12714-4","volume":"10","author":"P Ulz","year":"2019","unstructured":"Ulz, P. et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nat. Commun. 10, 4666 (2019).","journal-title":"Nat. Commun."},{"key":"1454_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","volume":"608","author":"C Herberts","year":"2022","unstructured":"Herberts, C. et al. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature 608, 199\u2013208 (2022).","journal-title":"Nature"},{"key":"1454_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23445-w","volume":"12","author":"P Peneder","year":"2021","unstructured":"Peneder, P. et al. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nat. Commun. 12, 3230 (2021).","journal-title":"Nat. Commun."},{"key":"1454_CR44","doi-asserted-by":"publisher","first-page":"672","DOI":"10.4143\/crt.2018.137","volume":"51","author":"YR Kim","year":"2019","unstructured":"Kim, Y. R., Kim, D. & Kim, S. Y. Prediction of acquired taxane resistance using a personalized pathway-based machine learning method. Cancer Res. Treat. 51, 672\u2013684 (2019).","journal-title":"Cancer Res. Treat."},{"key":"1454_CR45","doi-asserted-by":"publisher","unstructured":"Pudova, E. et al. Non-coding RNAs and the development of chemoresistance to docetaxel in prostate cancer: regulatory interactions and approaches based on machine learning methods. Life 13, https:\/\/doi.org\/10.3390\/life13122304 (2023).","DOI":"10.3390\/life13122304"},{"key":"1454_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37647-x","volume":"14","author":"AC de Jong","year":"2023","unstructured":"de Jong, A. C. et al. Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning. Nat. Commun. 14, 1968 (2023).","journal-title":"Nat. Commun."},{"key":"1454_CR47","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/pros.22583","volume":"73","author":"C Liu","year":"2013","unstructured":"Liu, C. et al. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 73, 418\u2013427 (2013).","journal-title":"Prostate"},{"key":"1454_CR48","doi-asserted-by":"publisher","unstructured":"Lai, C. J. et al. CD44 promotes migration and invasion of docetaxel-resistant prostate cancer cells likely via induction of Hippo-YAP signaling. Cells 8, https:\/\/doi.org\/10.3390\/cells8040295 (2019).","DOI":"10.3390\/cells8040295"},{"key":"1454_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0556-9","volume":"15","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol. Cancer 15, 70 (2016).","journal-title":"Mol. Cancer"},{"key":"1454_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35856-y","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Niche stiffness sustains cancer stemness via TAZ and NANOG phase separation. Nat. Commun. 14, 238 (2023).","journal-title":"Nat. Commun."},{"key":"1454_CR51","doi-asserted-by":"publisher","first-page":"22361","DOI":"10.18632\/oncotarget.4293","volume":"6","author":"N Kawamura","year":"2015","unstructured":"Kawamura, N. et al. CRISPR\/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells. Oncotarget 6, 22361\u201322374 (2015).","journal-title":"Oncotarget"},{"key":"1454_CR52","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/pros.22870","volume":"74","author":"S Kregel","year":"2014","unstructured":"Kregel, S., Szmulewitz, R. Z. & Vander Griend, D. J. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate 74, 1530\u20131543 (2014).","journal-title":"Prostate"},{"key":"1454_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3100-4","volume":"17","author":"DJ Lundon","year":"2017","unstructured":"Lundon, D. J. et al. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation. BMC Cancer 17, 163 (2017).","journal-title":"BMC Cancer"},{"key":"1454_CR54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/aipo.2024.0004","volume":"1","author":"P Gerrard","year":"2024","unstructured":"Gerrard, P. et al. Analytical validation of a clinical grade prognostic and classification artificial intelligence laboratory test for men with prostate cancer. AI Precis. Oncol. 1, 119\u2013126 (2024).","journal-title":"AI Precis. Oncol."},{"key":"1454_CR55","doi-asserted-by":"publisher","first-page":"EVIDoa2300023","DOI":"10.1056\/EVIDoa2300023","volume":"2","author":"DE Spratt","year":"2023","unstructured":"Spratt, D. E. et al. Artificial intelligence predictive model for hormone therapy use in prostate cancer. NEJM Evid. 2, EVIDoa2300023 (2023).","journal-title":"NEJM Evid."},{"key":"1454_CR56","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","volume":"29","author":"SC Baca","year":"2023","unstructured":"Baca, S. C. et al. Liquid biopsy epigenomic profiling for cancer subtyping. Nat. Med. 29, 2737\u20132741 (2023).","journal-title":"Nat. Med."},{"key":"1454_CR57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3816\/CGC.2006.n.019","volume":"5","author":"WK Oh","year":"2006","unstructured":"Oh, W. K. et al. Development of an integrated prostate cancer research information system. Clin. Genitourin. Cancer 5, 61\u201366 (2006).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1454_CR58","doi-asserted-by":"crossref","unstructured":"Benjamin, D. et al. Calling somatic SNVs and indels with Mutect2. BioRxiv 861054 (2019).","DOI":"10.1101\/861054"},{"key":"1454_CR59","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nbt.4235","volume":"36","author":"R Poplin","year":"2018","unstructured":"Poplin, R. et al. A universal SNP and small-indel variant caller using deep neural networks. Nat. Biotechnol. 36, 983\u2013987 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1454_CR60","doi-asserted-by":"publisher","first-page":"D100","DOI":"10.1093\/nar\/gky1128","volume":"47","author":"I Yevshin","year":"2018","unstructured":"Yevshin, I., Sharipov, R., Kolmykov, S., Kondrakhin, Y. & Kolpakov, F. GTRD: a database on gene transcription regulation\u20142019 update. Nucleic Acids Res. 47, D100\u2013D105 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1454_CR61","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"1454_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45839-z","volume":"9","author":"HM Amemiya","year":"2019","unstructured":"Amemiya, H. M., Kundaje, A. & Boyle, A. P. The ENCODE Blacklist: identification of problematic regions of the genome. Sci. Rep. 9, 9354 (2019).","journal-title":"Sci. Rep."},{"key":"1454_CR63","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature10730","volume":"481","author":"CS Ross-Innes","year":"2012","unstructured":"Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389\u2013393 (2012).","journal-title":"Nature"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01454-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:02:05Z","timestamp":1783040525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01454-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01454-6","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.D.C.: none. A.Z.: none. D.D.Y.: none. E.F.: none. R.P.: none. J.C.: none. P.C.: none. I.B.R.: none. B.H.: none. M.R.-Y.: none. J.T.: none. C.C.: none. M.F.: none. B.W.: none. B.R. has filed institutional patents on methods for clinical interpretation. J.P.: none. P.S.N. served as a paid consultant to AstraZeneca, Genentech, and Pfizer and received research support from Janssen for work unrelated to the present study. F.W.H.: none. E.M.V.A.: advisory\/consulting: Enara Bio, Manifold Bio, Monte Rosa, Novartis Institute for Biomedical Research, Serinus Bio, TracerBio. Research support: Novartis, BMS, Sanofi, NextPoint. Equity: Tango Therapeutics, Genome Medical, Genomic Life, Enara Bio, Manifold Bio, Microsoft, Monte Rosa, Riva Therapeutics, Serinus Bio, Syapse, TracerDx. Travel reimbursement: None. Speaking fees: TD Cowen. Patents: institutional patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation; intermittent legal consulting on patents for Foaley & Hoag. Editorial Boards: Science Advances. G.H.: consultant: quest diagnostics (unrelated to this work); patents: US11479878B2, WO2022217096A3. A.D.C.: Honoraria: OncLive, Targeted Oncology, Aptitude Health, Great Debates and Updates, Pfizer, Springer, Lantheus, Wiley, Color Genomics, Physicians\u2019 Education Resource, Outcomes4Me, Bayer, DAVA Oncology, Medscape, MDoutlook, Conexiant, Total Health, Curio, MECC; Advisory Board: Tolmar, Janssen\/Johnson & Johnson, Sanofi Aventis, Pfizer, Astellas, Bayer, Daiichi Sankyo, Boundless Bio, Novartis; Research Funding: Merck (Institution), Bayer (Institution), Eli Lilly (Institution), Pfizer (Institution), Sumitomo Pharma America (Institution) for work unrelated to this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}